Obesity Hypoventilation Syndrome (Pickwickian Syndrome)

HYPOVENTILATION syndrome in very obese persons with excessive ADIPOSE TISSUE around the ABDOMEN and DIAPHRAGM. It is characterized by diminished to absent ventilatory chemoresponsiveness; chronic HYPOXIA; HYPERCAPNIA; POLYCYTHEMIA; and long periods of sleep during day and night (HYPERSOMNOLENCE). It is a condition often related to OBSTRUCTIVE SLEEP APNEA but can occur separately.
Also Known As:
Pickwickian Syndrome; Syndrome, Pickwickian; Hypoventilation Syndrome, Obesity; Syndrome, Obesity Hypoventilation
Networked: 110 relevant articles (6 outcomes, 6 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Hypoventilation
2. Obstructive Sleep Apnea
3. Neuromuscular Diseases (Neuromuscular Disease)
4. Sleep Apnea Syndromes (Sleep Apnea)
5. Weight Loss (Weight Reduction)


1. Piper, Amanda J: 4 articles (05/2014 - 01/2006)
2. Monneret, Denis: 3 articles (11/2015 - 04/2010)
3. Contal, Olivier: 3 articles (07/2015 - 01/2013)
4. Adler, Dan: 3 articles (07/2015 - 01/2013)
5. Janssens, Jean-Paul: 3 articles (07/2015 - 11/2008)
6. Grunstein, Ronald R: 3 articles (05/2014 - 01/2006)
7. Yee, Brendon J: 3 articles (05/2014 - 01/2006)
8. Esquinas, Antonio M: 3 articles (05/2013 - 02/2013)
9. Borel, Jean-Christian: 3 articles (01/2013 - 04/2010)
10. Pépin, Jean-Louis: 2 articles (07/2015 - 01/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Obesity Hypoventilation Syndrome:
1. Carbon DioxideIBA
2. Carbon MonoxideIBA
3. HormonesIBA
4. OxygenIBA
5. Interleukin-6 (Interleukin 6)IBA
6. LeptinIBA
8. ProgesteroneFDA LinkGeneric
9. GasesIBA
10. Oxyhemoglobins (Oxyhemoglobin)IBA
07/01/1985 - "Oxyhemoglobin saturation during sleep in subjects with and without the obesity-hypoventilation syndrome."
01/01/2008 - "Current recommendations follow: (1) APAP devices are not recommended to diagnose OSA; (2) patients with congestive heart failure, patients with significant lung disease such as chronic obstructive pulmonary disease; patients expected to have nocturnal arterial oxyhemoglobin desaturation due to conditions other than OSA (e.g., obesity hypoventilation syndrome); patients who do not snore (either naturally or as a result of palate surgery); and patients who have central sleep apnea syndromes are not currently candidates for APAP titration or treatment; (3) APAP devices are not currently recommended for split-night titration; (4) certain APAP devices may be used during attended titration with polysomnography to identify a single pressure for use with standard CPAP for treatment of moderate to severe OSA; (5) certain APAP devices may be initiated and used in the self-adjusting mode for unattended treatment of patients with moderate to severe OSA without significant comorbidities (CHF, COPD, central sleep apnea syndromes, or hypoventilation syndromes); (6) certain APAP devices may be used in an unattended way to determine a fixed CPAP treatment pressure for patients with moderate to severe OSA without significant comorbidities (CHF, COPD, central sleep apnea syndromes, or hypoventilation syndromes); (7) patients being treated with fixed CPAP on the basis of APAP titration or being treated with APAP must have close clinical follow-up to determine treatment effectiveness and safety; and (8) a reevaluation and, if necessary, a standard attended CPAP titration should be performed if symptoms do not resolve or the APAP treatment otherwise appears to lack efficacy."

Therapies and Procedures

1. Positive-Pressure Respiration (PEEP)
2. Continuous Positive Airway Pressure
3. Artificial Respiration (Mechanical Ventilation)
4. Mechanical Ventilators (Ventilator)
5. Analgesia